Chugai Pharmaceutical Co Ltd

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Chugai Pharmaceutical Co., Ltd. engages in the research, development, manufacturing, sale, importation, and exportation of pharmaceuticals. Its operations are carried out through the Domestic and Overseas businesses. The Domestic Business covers the manufacturing, research, and development operations in Japan. The Overseas business comprises of sales and production in Europe, Taiwan and China. The company was founded by Juzo Ueno on March 10, 1925 and is headquartered in Tokyo, Japan.

Chugai Pharmaceutical Co., Ltd. (OTCPK:CHGCF) Q3 2024 Earnings Conference Call October 25, 2024 5:00 AM ET Company Participants Kae Miyata - Corporate Communications Department Osamu Okuda - President and CEO Tsukasa Kusano - Executive Vice President, Head, Project and Lifecycle Management Unit Iwaaki Taniguchi - Chief Financial Officer Junichi Takano - Head, Marketing and Sales Division Conference Call Participants Seiji Wakao - JPMorgan Hidemaru Yamaguchi - Citigroup Securities Shinichiro Muraoka - Morgan Stanley MUFG Securities Tony Ren - Macquarie Capital Hiroshi Wada - SMBC Nikko Securities Kazuaki Hashiguchi - Daiwa Securities Kasumi Haruta - UBS Securities Kae Miyata Thank you for joining Chugai Pharmaceutical's Earnings Call on the Financial Results for the Fiscal Year 2024 Third Quarter.

Chugai Pharmaceutical Co., Ltd. (CHGCF) Q3 2024 Earnings Call Transcript

Chugai Pharmaceutical Co., Ltd. (OTCPK:CHGCF) Q2 2024 Earnings Conference Call July 24, 2024 4:00 AM ET Company Participants Kae Miyata - Head of Corporate Communications Osamu Okuda - President and Chief Executive Officer Tsukasa Kusano - Executive Vice President, Head of Project & Lifecycle Management Unit Iwaaki Taniguchi - Chief Financial Officer Conference Call Participants Shinichiro Muraoka - Morgan Stanley Matsubara - Nomura Securities Kasumi Haruta - UBS Securities Seiji Wakao - JPMorgan Securities Japan Co., Ltd.

Chugai Pharmaceutical Co., Ltd. (CHGCF) Q2 2024 Earnings Call Transcript

Chugai Pharmaceutical Co., Ltd. (OTCPK:CHGCF) Q1 2024 Earnings Conference Call April 24, 2024 5:00 AM ET

Chugai Pharmaceutical Co., Ltd. (CHGCF) Q1 2024 Earnings Call Transcript

After losing some value lately, a hammer chart pattern has been formed for Chugai Pharmaceutical Co., Ltd. Unsponsored ADR (CHGCY), indicating that the stock has found support.

Chugai Pharmaceutical Co., Ltd. Unsponsored ADR (CHGCY) May Find a Bottom Soon, Here's Why You Should Buy the Stock Now

Chugai Pharmaceutical Co., Ltd. Unsponsored ADR (CHGCY) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

Chugai Pharmaceutical Co., Ltd. Unsponsored ADR (CHGCY) Upgraded to Buy: Here's Why

If you are looking for stocks that are well positioned to maintain their recent uptrend, Chugai Pharmaceutical Co., Ltd. Unsponsored ADR (CHGCY) could be a great choice.

Chugai Pharmaceutical Co., Ltd. Unsponsored ADR (CHGCY) Is a Great Choice for 'Trend' Investors, Here's Why

Chugai Pharmaceutical Co., Ltd. Unsponsored ADR (CHGCY) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects.

Chugai Pharmaceutical Co., Ltd. Unsponsored ADR (CHGCY) Upgraded to Buy: Here's What You Should Know

Cadence Design Systems

Coca-Cola

As we progress through earnings season several top-rated Zacks stocks are expected to report their first quarter results on Monday, April 24.

3 Stocks to Consider with Earnings Approaching

News for Chugai Pharmaceutical Co Ltd Stock (CHGCY)